

1 **Pyriproxyfen is metabolized by P450s associated with pyrethroid resistance in**  
2 ***An. gambiae***

3

4 **Short Title:** Pyriproxyfen P450 metabolism

5

6 Cristina Yunta<sup>1</sup>, Nelson Grisales<sup>1</sup>, Szilárd Nász<sup>2</sup>, Kay Hemmings<sup>1</sup>, Patricia Pignatelli<sup>1</sup>,  
7 Michael Voice<sup>3</sup>, Hilary Ranson<sup>1</sup>, Mark J I Paine<sup>1</sup>. \*

8 <sup>1</sup>Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK

9 <sup>2</sup>Syngenta, Product Metabolism and Analytical Sciences, Jealott's Hill International  
10 Research Centre, Bracknell, RG42 6EY, UK

11 <sup>3</sup>Cypex Ltd, Tom McDonald Avenue, Dundee, DD2 1NH, UK

12

13 \* corresponding author, Email: [mark.paine@lstmed.ac.uk](mailto:mark.paine@lstmed.ac.uk)

14

15 **Abstract**

16 Pyrethroid resistance is widespread in the malaria vector *Anopheles gambiae* leading  
17 to concerns about the future efficacy of bednets with pyrethroids as the sole active  
18 ingredient. The incorporation of pyriproxyfen (PPF), a juvenile hormone analogue, into  
19 pyrethroid treated bednets is being trialed in Africa. Pyrethroid resistance is commonly  
20 associated with elevated levels of P450 expression including CYPs 6M2, 6P2, 6P3,  
21 6P4, 6P5, 6Z2 and 9J5. Having expressed these P450s in *E. coli* we find all are  
22 capable of metabolizing PPF. Inhibition of these P450s by permethrin, deltamethrin  
23 and PPF was also examined. Deltamethrin and permethrin were moderate inhibitors  
24 (IC<sub>50</sub> 1 – 10 µM) of diethoxyfluorescein (DEF) activity for all P450s apart from CYP6Z2  
25 (IC<sub>50</sub> >10 µM), while PPF displayed weaker inhibition of all P450s (IC<sub>50</sub> >10 µM) except  
26 CYP's 6Z2 and 6P2 (IC<sub>50</sub> 1 – 10 µM). We found evidence of low levels of cross  
27 resistance between PPF and other insecticide classes by comparing the efficacy of

28 PPF in inhibiting metamorphosis and inducing female sterility in an insecticide  
29 susceptible strain of *An. gambiae* and a multiple resistant strain from Cote d'Ivoire.

30

### 31 **Keywords**

32 Pyriproxyfen, insecticide resistance, P450, Olyset Duo

33

### 34 **Abbreviations**

35 PPF, pyriproxyfen; ALA, 5-Aminolevulinic acid; DEF, diethoxyfluorescein; CPR,  
36 cytochrome P450 reductase.

37

## 38 **1. Introduction**

39 Malaria control is reliant on the use of insecticides. The dramatic reductions in malaria  
40 cases in Africa that have occurred over the last 15 years have been largely attributed  
41 to methods targeting the adult mosquito, primarily via the use of long lasting  
42 insecticidal nets (LLINs) treated with pyrethroids and, to a lesser extent indoor residual  
43 spraying (IRS) with pyrethroids and DDT and, more recently, carbamates and  
44 organophosphates (Bhatt *et al.*, 2015; Ranson and Lissenden, 2016). Resistance to  
45 pyrethroids is now widespread in the major malaria vectors in Africa with resistance to  
46 other classes of public health insecticides also on the increase (Ranson and  
47 Lissenden, 2016). There is therefore an urgent need both for new insecticides to  
48 maintain the efficacy of these proven tools, and for new tools to reduce malaria  
49 transmission by the mosquito.

50

51 Pyriproxyfen (PPF) is a juvenile hormone analogue that inhibits metamorphosis. It has  
52 been used for several decades to protect against cotton pests (Carriere *et al.*, 2012)  
53 and its extremely low toxicity to humans has also enabled applications in public health  
54 such as addition to water storage containers to control *Aedes* populations (Darriet and  
55 Corbel, 2006; Lee, 2001). As PPF is active in very low concentrations, the active

56 ingredient can be disseminated by the insect itself; this autodissemination route was  
57 shown to be effective at controlling *Aedes* populations in trials in Peru (Devine et al.,  
58 2009). For malaria vectors, difficulties in identifying and treating the diverse breeding  
59 sites for malaria vectors have so far largely confined larviciding for malaria control to  
60 easy to reach urban areas but the possibility of using autodissemination strategies to  
61 distribute PPF to target *Anopheles* oviposition sites in rural areas is being explored.  
62 Currently, however, control of *Anopheles* mosquitoes is more commonly targeted at  
63 the adult stage, hence the impact of PPF on embryogenesis, shows the greatest  
64 promise for malaria control. Exposure to PPF effectively sterilizes female mosquitoes  
65 and has also been shown to reduce adult longevity (Ohashi et al., 2012; Ngufor et al.,  
66 2014). Sumitomo Chemicals Ltd has developed a LLIN incorporating both permethrin  
67 and PPF. This Olyset Duo<sup>®</sup>, net has been shown to be effective in laboratory and  
68 experimental hut trials (Aiku et al., 2006; Ngufor et al., 2014; Ohashi et al., 2012;  
69 Tsunoda et al., 2013) and is currently being evaluated in a randomised control trial in  
70 Burkina Faso to compare the efficacy of this combination net with conventional Olyset  
71 nets (Tiono et al., 2015).

72

73 However, concerns have been raised about the performance of Olyset Duo against  
74 pyrethroid resistant populations (Koffi et al., 2015). An experimental hut study of Olyset  
75 Duo carried out in an area where the *Anopheles gambiae* population has high levels  
76 of both target site and metabolic resistance to pyrethroids found no significant  
77 difference in the number of sterile mosquitoes in huts with Olyset Duo compared to  
78 control huts (Koffi et al., 2015).

79

80 Resistance to PPF has been reported in other insects including the greenhouse  
81 whitefly *Trialeurodes vaporariorum* (Karatolos et al., 2012) and the sweet potato whitefly,  
82 *Bemisia tabaci* (Rami Horowitz et al., 2003). Although the mechanisms of resistance

83 have not been fully described, elevated levels of genes involved in insect P450 and  
84 GST activity appear to be involved.

85

86 Several P450 enzymes have been implicated in the development of metabolic  
87 insecticide resistance in *An. gambiae* but a relatively small subset of this large enzyme  
88 family are consistently found up-regulated in pyrethroid resistant populations (David *et al.*,  
89 *et al.*, 2013, Inhgam *et al.*, 2015). This candidate list is predominated by three subfamilies  
90 of the CYP6 P450s: CYP6P, CYP6M and CYP6Z, but also includes CYP9J5  
91 (Hemingway *et al.*, 2013; Toé *et al.*, 2015) and the two CYP4G enzymes, CYP4G16  
92 and 17 (Jones *et al.*, 2013; Toé *et al.*, 2015). CYP6M2 and CYP6P3 are confirmed  
93 pyrethroid metabolisers but are also active against insecticides from other insect  
94 classes (Mitchell *et al.*, 2012; Muller *et al.*, 2008; Stevenson *et al.*, 2011). In contrast  
95 the CYP4G enzymes do not have detectable activity against insecticides but instead  
96 are believed to confer resistance via reducing insecticide uptake (Balabanidou *et al.*, in  
97 press).

98

99 Here, we expressed the CYPs 6M2, 6P1, 6P2, 6P3, 6P4, 6P5, 6Z2 and 9J5 in  
100 *Escherichia coli* and assessed their ability to metabolize PPF. We also assessed the  
101 likelihood of cross resistance between PPF and other insecticide classes by comparing  
102 the efficacy of PPF in inhibiting metamorphosis and inducing female sterility in an  
103 insecticide susceptible strain of *An. gambiae* and a multiple resistant strain from Cote  
104 d'Ivoire.

105

## 106 **2. Material and methods**

### 107 **2.1 Reagents**

108 Oligonucleotides were synthesized by Eurofins genomics and enzymes for DNA  
109 manipulation were supplied by Thermo Scientific. Isopropyl-β-D-thio-  
110 galactopyranoside (IPTG), 5-aminolevulinic acid (ALA), and 3-[(3-cholamidopropyl)-

111 dimethylammonio]-1-propanesulfonate (CHAPS) were supplied by Melford (UK).  
112 Insecticides were supplied by ChemService: 3-phenoxybenzyl (1*R,S*)-*cis,trans*-3-(2,2-  
113 dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate (permethrin, mixture of isomers),  
114 (*S*)- $\alpha$ -cyano-3-phenoxybenzyl (1*R,3R*)-*cis*-2,2-dimethyl-3-(2,2-dibromovinyl)-  
115 cyclopropanecarboxylate (deltamethrin) and pyriproxyfen. HPLC solvents were  
116 supplied by Fisher Scientific. Other chemicals were obtained from Sigma-Aldrich  
117 unless indicated otherwise.

118

## 119 **2.2 Gene cloning**

120 Total RNA was extracted with either the Arcturus PicoPure Kit (Applied Biosystems)  
121 or TRI reagent (Sigma-Aldrich) from ten adult *An. gambiae* mosquitoes from the  
122 Kisumu strain. Complementary DNA was prepared using Superscript III (Invitrogen)  
123 with an oligo(dT)<sub>20</sub> primer and used as a template for amplifying full-length genes with  
124 KOD DNA polymerase (Merk Chemicals). The gene-specific primers used in these  
125 high-fidelity PCRs were designed according to the *An. gambiae* genome sequence  
126 (Table S1). PCR products from P450s, summarized in Table S2, were ligated into  
127 pGEM T-easy (Promega) and sequenced. For expression, the ompA leader sequence  
128 (ompA), was engineered onto the amino-terminus to direct the P450 to the *E. coli* outer  
129 membrane during expression as previously described (Mclaughlin *et al.*, 2008;  
130 Stevenson *et al.*, 2011). The ompA-leader was fused to the P450 cDNA in frame with  
131 the P450 initiation codon by fusion PCR. The ompA-leader was fused to the P450  
132 cDNA in frame with the P450 initiation codon by fusion PCR. The ompA P450 fusion  
133 was flanked at the 5' and 3' ends with NdeI and NotI respectively for ligation into  
134 NdeI/NotI digested pCWori+.

135

136 For CYP6M2 and CYP6P3 a single plasmid expression system for the P450 and CPR  
137 was constructed by ligating the expression cassette (cDNA and *tactac* promoter)  
138 containing the *An. gambiae* NADPH P450 reductase (CPR) cDNA from the

139 pACYC:AgCPR plasmid described above into the pCW:P450 expression plasmid. In  
140 the new construct the expression of each protein is under the control of its own *tactac*  
141 promoter so expression of both proteins is induced by the addition of IPTG to the  
142 culture.

143

### 144 **2.3 Preparation of membranes expressing P450 and AgCPR**

145 For dual plasmid co-expression of P450 and AgCPR (all P450s except CYP6M2 and  
146 CYP6P3), competent *E. coli* DH5 $\alpha$  cells were co-transformed with pCW:P450 plasmid  
147 and pACYC:AgCPR (Stevenson *et al.*, 2011). Cultures, generally 0.2 l, were  
148 supplemented with 1.0 mM ALA and incubated at 23°C for 18 – 24 hours after 1mM  
149 IPTG induction. P450 expression, *E. coli* membrane isolation and determination of  
150 P450 and AgCPR content was performed as previously described (Mclaughlin *et al.*,  
151 2008; Stevenson *et al.*, 2012). Samples were stored in aliquots at -80 °C. *An. gambiae*  
152 cytochrome  $b_5$  ( $b_5$ ) was prepared as described previously to supplement enzyme  
153 reactions at a 10:1 molar ratio,  $b_5$ :P450 (Stevenson *et al.*, 2011).

154

155 For CYP6M2 and CYP6P3, *E. coli* JM109 were transformed with the single plasmid  
156 system for the co-expression of AgCPR. Cultures were grown in 10 l stirred batch,  
157 glass fermenters and were harvested and processed to produce membrane fractions  
158 containing the CYP and CPR using the procedures described above, scaled to account  
159 for the larger culture volumes. Cytochrome  $b_5$  was added to the CYP6P3 bacterial  
160 membrane preparations at a 10:1 molar ratio,  $b_5$ :P450. After the addition of the  
161 cytochrome  $b_5$  the membrane preparation was gently stirred at 4°C for 30 min to allow  
162 time for the incorporation of the cytochrome  $b_5$  into the membranes before aliquotting  
163 and freezing at -80 °C.

164

### 165 **2.4 Pyriproxyfen metabolism**

166 Incubations of a 200  $\mu$ l reaction mix containing 20  $\mu$ M insecticide, 0.1  $\mu$ M of the  
167 recombinant enzyme, 1.0  $\mu$ M b<sub>5</sub>, 0.2 M of TrisHCl at pH 7.4, 0.25 mM MgCl<sub>2</sub>, 1 mM  
168 glucose-6-phosphate, 0.1 mM NADP<sup>+</sup> and 1 unit/mL glucose-6-phosphate  
169 dehydrogenase (G6PDH) were carried out in the presence or absence of 10  $\mu$ M  
170 piperonyl butoxide (PBO) at 30°C with shaking (1200 rpm) for 90 min and stopped by  
171 addition of 200  $\mu$ l of methanol. Shaking was carried for an additional 10 min before  
172 centrifuging the reactions at 20000 g for 20 min. 150  $\mu$ l of supernatant was used for  
173 HPLC analysis. Reactions were performed in triplicate and a paired T-test of sample  
174 reactions (+NADPH) vs negative control (-NADPH) used for statistical measurements  
175 of substrate depletion.

176

177 For reciprocal IC<sub>50</sub> measurements of CYP6P3 metabolism of PPF and permethrin,  
178 enzyme reactions were carried out with PPF or permethrin added as inhibitors (at  
179 concentrations ranging from 0 - 1.6 mM or 0 -3.2 mM respectively) to the reaction  
180 mix to titer their effect on the insecticide turnover (fixed at 20  $\mu$ M). Three replicates of  
181 positive and negative control reactions were run for each P450/inhibitor combination.

182

### 183 **2.5 High-pressure liquid chromatography (HPLC) analysis**

184 Samples were analyzed by high-pressure liquid chromatography, HPLC (Agilent 1100  
185 series). The quantity of insecticide remaining in the samples was determined by  
186 reverse-phase HPLC with a monitoring absorbance at 232 nm using a C18 column,  
187 Acclaim 120, Thermo Scientific. 100  $\mu$ l of sample was loaded with a flow-rate 1 ml/min  
188 at 23 °C into an isocratic mobile phase 90% methanol and 10% water. The retention  
189 time for PPF is 7.4 min and for PBO 7.1 min.

190

191 The same conditions were applied for HPLC analysis for the PPF/permethrin inhibition  
192 assays. Retention time for trans- and cis-permethrin is 11.8 min and 14.1 min  
193 respectively.

194

195

### 196 **Mass spectrometry analysis for pyriproxyfen metabolism**

197 PPF metabolism by CYP6P3 was examined by mass spectrometry to confirm oxidation  
198 and identify the metabolites produced. Aliquots (5  $\mu$ l) of organic solvent-quenched  
199 reaction supernatant were injected onto a high resolution Thermo Q-Exactive mass  
200 spectrometer (MS) that was coupled to a 1290 series Agilent LC system. The  
201 chromatographic separation was performed on a Waters Acquity BEH C18 (2.1 x 50  
202 mm; 1.7  $\mu$ m) analytical column at 30 °C using a mixture of water (0.1% formic acid) (A)  
203 and acetonitrile (0.1% formic acid) (B) as mobile phase. In the 12 minutes run time the  
204 gradient program was as follows: 5% B in 0-1 minute; 5% B to 100% B in 1-8 minutes;  
205 100% B in 8-10 minutes; 100% B to 5% B in 10-10.1 minutes; 5% B in 10.1-12 minutes.  
206 During the analysis the MS was operated in positive ion full scan mode (mass range:  
207 100-1000 m/z) at 35K resolution using a constant heated electrospray capillary  
208 temperature (320 °C), spray voltage (3500 V), sheath gas (55 arbitrary units) and  
209 auxiliary gas flow rate (10 arbitrary units).

210

### 211 **2.6 Diethoxyfluorescein metabolism**

212 Diethoxyfluorescein (DEF) substrate was dissolved in DMSO, with final concentration  
213 of 2 % per assay. All test compounds were dissolved in DMSO, with a final solvent  
214 concentration <2 % per assay. For calculation of the kinetic parameters ( $K_M$  and  $V_{max}$ ),  
215 each P450 was used at a final concentration of 10 nM (1 pmol/reaction) and DEF  
216 concentrations in the range: 0, 0.31, 0.63, 1.25, 2.5, 5, 10 and 20  $\mu$ M. DEF reactions  
217 were carried out at 25 °C in 50 mM KPi at pH 7.4 containing 1 mM glucose-6-  
218 phosphate (G6P), 0.1 mM NADP<sup>+</sup>, 0.25 mM MgCl<sub>2</sub>, and cytochrome b<sub>5</sub> at a 10:1 molar  
219 ratio, b<sub>5</sub>:P450. NADP<sup>+</sup> and G6P were excluded from the minus NADPH controls.

220



221 Variable ligand concentrations were used for IC<sub>50</sub> calculations with DEF used at ~ K<sub>M</sub>  
222 for each P450 (i.e. 0.5, 1.4, 0.7, 1.0, 3.5 and 0.5 μM for CYP6M2, CYP6P2, CYP6P3,  
223 CYP6P4, CYP9J5, and CYP6Z2 respectively) and 0.1 μM P450. Three replicates of  
224 positive and negative control reactions were run for each P450/substrate combination  
225 in opaque white 96-well (flat-based) plates in triplicate. The fluorescent reactions were  
226 monitored in a fluorescence plate-reader (Ex = 485 nm, Em = 520 nm) continuously  
227 over 20 minutes time period after the addition of NADPH regenerating system. The  
228 rate of fluorescent molecules produced per P450 molecule per min (turnover) was  
229 determined by linear regression of the measurements between 3 min and 10 min after  
230 the reactions began. The Michaelis-Menten and IC<sub>50</sub> fitting calculations were  
231 performed using Graphpad Prism 6. Data were fitted to the dose-response model and  
232 plots with R<sup>2</sup> <0.95 were rejected.

233

## 234 **2.8 *In vivo* studies**

235 Two strains of mosquitoes were used to assess the impact of exposure to PPF on life  
236 history. The Kisumu strain of *An. gambiae* originates from Kenya and is susceptible to  
237 all insecticide classes used in public health whereas the Tiassalé strain from Cote  
238 d'Ivoire shows resistance to four classes (pyrethroids, carbamates, organophosphates  
239 and the organochlorine DDT) (Constant *et al*, 2012). Resistance in the Tiassalé strain  
240 is mediated by multiple mechanisms, including the overexpression of cytochrome  
241 P450s, notably CYP6P3, 6P4 and 6M2 (Constant *et al*, 2014). Both mosquito strains  
242 were reared in the insectaries at the Liverpool School of Tropical Medicine under a  
243 12:12 photoperiod at 27°C and 70-80% humidity.

244

245 To measure the effect of PPF on metamorphosis, SumiLarv®0.5G (Sumitomo  
246 Chemicals Ltd) was ground into a fine powder and dissolved in water to prepare a  
247 stock solution of 1000 ppm SumiLarv (50 ppm active ingredient). The solution was left  
248 overnight dissolving on a magnetic stirrer, protected from light. Serial dilutions were

249 prepared and the following PPF concentrations were tested: 0.001 ppb, 0.005 ppb,  
250 0.07 ppb, 0.1 ppb, 1 ppb, 5 ppb and 10 ppb. Four replicates of 25 3<sup>rd</sup> instar mosquitoes  
251 were exposed to each of the SumiLarv concentrations in paper cups for up to 8 days.  
252 Larvae were fed Tetramin® baby fish food every day and cups covered with netting to  
253 prevent adults escaping. The number of live and dead larvae, pupae and adults was  
254 recorded every 24 hours until all individuals were emerged as adults or dead. Adults  
255 and dead pupae were removed daily. The Dose Effect function on XLSTAT (Microsoft)  
256 was used to estimate the concentration resulting in 50 % emergence inhibition (EI50).

257

258 To compare the impact of PPF on adult mosquitoes of the two strains, we measured  
259 the ability of this compound to impair ovary development. Borosilicate glass tubes (30  
260 cm long, 11 mm wide) were impregnated with three different concentrations of PPF  
261 (ai): 0.55 mg/m<sup>2</sup>, 2.75 mg/m<sup>2</sup> and 5.5 mg/m<sup>2</sup>. An additional tube impregnated only with  
262 the solvent (acetone) was used as a negative control. Tubes were used on the day of  
263 preparation. Two groups of fifteen 5-7 days old female mosquitoes from Tiassalé and  
264 Kisumu strains were tested for each concentration (n= 30). After 60 minutes  
265 acclimation in paper cups, they were transferred to the glass tubes and exposed for 3  
266 minutes. Mosquitoes were then returned to the paper cups and left for 24 hours with a  
267 10% sucrose solution. 24 hours after exposure the mosquitoes were bloodfed and any  
268 mosquitoes which did not feed were removed. Mosquitoes were retained in insectary  
269 conditions with access to sugar water for five days and then dissected and the  
270 morphology of the ovaries assessed as normal (loose, well developed eggs) or  
271 abnormal (non-detachable, bubble-like eggs). Dead mosquitoes or mosquitoes not  
272 presenting egg development were discarded and removed from the analysis.

273

274 To confirm that formulated products containing PPF also impaired egg development,  
275 mosquitoes were exposed to Olyset Duo nets, nets containing 1 % PPF only (supplied  
276 by Sumitomo Chemicals Ltd), conventional Olyset nets or untreated nets. Batches of

277 10 3-5 days old Tiassalé mosquitoes were exposed to the nets for 3 minutes following  
278 WHO standard protocols for cone bioassays. Twenty-four hours after the exposure,  
279 mosquitoes were bloodfed and left in paper cups with 10% sucrose solution. Dead and  
280 non-bloodfed mosquitoes were removed from the experiment. After 5 days surviving  
281 mosquitoes were dissected and the morphology of the ovaries examined as described  
282 above. To assess the effects of short exposures to PPF LLINs, an additional set of  
283 cone bioassays was performed, as described above, except exposure time was  
284 reduced to 30 seconds.

285

### 286 **3. Results and Discussion**

287 This study was motivated by concerns over cross resistance between pyrethroid  
288 insecticides and the insect growth regulator, PPF. Cross resistance between  
289 insecticide classes with different modes of action, mediated by cytochrome P450s, has  
290 previously been demonstrated in *An. gambiae* (Constant *et al.*, 2014; Mitchell *et al.*,  
291 2012) and here we investigated whether these same P450 enzymes can also  
292 metabolize PPF. CYP6M2, CYP6P3 and CYP6Z2 have previously been expressed in  
293 bacterial expression systems but we extended the panel of recombinant enzymes to  
294 include a further three *An. gambiae* CYP6P P450s implicated in pyrethroid resistance  
295 in Cote d'Ivoire (Constant *et al.*, 2014) and CYP9J5, which has been found over  
296 expressed in pyrethroid resistant populations from Bioko Island (Hemingway *et al.*,  
297 2013) and Burkina Faso (Toé *et al.*, 2015).

298

#### 299 **3.1 Functional expression of P450s in *E. coli***

300 P450s require electrons from NADPH-cytochrome P450 oxido-reductase (CPR) for  
301 catalysis, thus new candidate *An. gambiae* P450s were co-expressed with AgCPR in  
302 *E. coli* using *ompA* and *pelB* leader sequences to direct the enzymes to the inner  
303 bacterial membrane as previously with CYP6M2 and CYP6P3 (Muller *et al.*, 2008;  
304 Stevenson *et al.*, 2011). CYP's 6P1, 6P2, 6P4, 6P5, 9J5 and 6M1 were co-transformed

305 with AgCPR-pACYC for *E. coli* expression, producing characteristic CO-reduced  
306 spectra indicative of active P450 (Fig. S1). The yields of P450 were in the range 10 –  
307 100 nmol/L, with CYP6P5 producing the lowest quantities of P450 (~ 10 nmol/L; Table  
308 S3). CYPs 6P1 and 6M1 failed to express functional P450.

309

310 CYP6M2 and CYP6P3 have previously been expressed following co-transformation  
311 with AgCPR on separate plasmids. Here, these enzymes were co-expressed in  
312 tandem with AgCPR on a single from the P450 expression plasmid, pCWori+ to  
313 facilitate scaled 10 l fermentor expression. Tandem expression from the single plasmid  
314 produced higher CPR:P450 ratios. The fluorogenic substrate DEF was used to  
315 estimate the kinetic parameters of the tandemly expressed recombinant proteins  
316 against dual plasmid protein expression (Table 1) and used in dose-response  
317 experiments to determine the inhibitory effect of permethrin, deltamethrin and  
318 pyriproxyfen in its metabolism. As expected, since CPR is rate limiting, the  $V_{max}$  values  
319 were 3 - 6 fold higher using the single plasmid in tandemly expressed membranes  
320 compared with dual plasmid expression, consistent with the elevated levels of CPR.  
321 The  $K_M$  value is the concentration of DEF required to reach max reaction velocity and  
322 independent of the enzyme concentration. The single versus double plasmid  $K_M$   
323 values for CYP6M2 (0.4 vs 0.5  $\mu$ M) and CYP6P3 (0.7 vs 0.9  $\mu$ M) were similar, again  
324 consistent with higher CPR levels increasing reaction rates through enhanced electron  
325 transfer rather than effects on substrate binding.

326

### 327 **3.2 PPF metabolism**

328 The ability of the *An. gambiae* P450s to metabolize PPF was tested by measuring  
329 substrate turnover (substrate disappearance over time) in the presence and absence  
330 of NADPH. We also included PBO in parallel reactions as further validation of P450  
331 induced substrate depletion (Fig. S2). PBO is an inhibitor of P450 monooxygenase  
332 activity and a common insecticide synergist (Vijayan *et al.*, 2007). All seven P450s

333 metabolized PPF to some degree with the percentage PPF depletion ranging from  
334 24.78 % for CYP9J5 to 100% for CYP6P3, and PPF depletion was inhibited by PBO  
335 for each P450 tested (Table 2). Since *E. coli* membranes expressing CYP6M2 and  
336 CYP6P3 had higher levels of CPR, the rates of activity were not comparable with the  
337 rest of the P450s. However, it is notable that, with the exception of CYP6P5, all  
338 members of the CYP6P family and CYP6Z2 produced high levels of PPF depletion (58  
339 - 100%). CYP6Z2 is of interest since it is found overexpressed in pyrethroid resistant  
340 populations of *An. gambiae*, but metabolises the pyrethroid metabolites 3-  
341 phenoxbenzoic alcohol and aldehyde rather than the parent compound (Chandor-  
342 Proust et al., 2013). Here CYP6Z2 appears to play a direct role in the primary  
343 metabolism of PPF, thus may have an influential role in PPF clearance and potentially  
344 insecticide resistance.

345

346 Mass spectrometry analysis of the PPF metabolites generated by CYP6P3, the  
347 strongest metabolizer was carried out to confirm oxidation and identify possible  
348 metabolites. Expected metabolites included 4'-OH-PPF, 5''-OH- PPF and 5'',4'-OH-  
349 PPF, that have been previously identified from the *in vitro* metabolism of PPF by  
350 microsomes from housefly larvae (Zhang et al., 1998). CYP6P3 generated three  
351 metabolite peaks (Fig. S3). The extracted ion chromatograms of [M+H]<sup>+</sup> generated two  
352 peaks (6.9 min and 7.1 min), with molecular mass ( $m/z=338.1387$ ) corresponding to  
353 the addition of a hydroxyl group ( $m/z=16$ ), consistent with 4'-OH-pyriproxyfen and 5''-  
354 OH-pyriproxyfen production. Furthermore, the data showed signs of a metabolite with  
355 molecular mass 32  $m/z$  larger than PPF, equivalent to a double hydroxylation,  
356 potentially 5'',4'-OH-PPF resulting from secondary metabolism of 5''-OH-PPF and/or  
357 4'-OH-PPF metabolites. This was, however, not confirmed chromatographically as  
358 analytical reference standards were not available for the analysis. Further collision  
359 mass spectrometry or NMR is required to confirm the identity of the metabolites.

360

361 Since PPF is being used in combination with pyrethroids in bednets we were interested  
362 in potential synergistic effects. We therefore measured the IC<sub>50</sub> values of PPF,  
363 deltamethrin and permethrin to compare relative strengths of DEF metabolism  
364 inhibition against the P450s (Table 3). The fluorescent substrate, DEF, was used for  
365 monitoring P450 activity using a 96 well microtiter plate format. In drug screens,  
366 compounds are generally categorized according to their activity as P450 inhibitors as  
367 potent inhibitors (IC<sub>50</sub> <1 μM), moderate (IC<sub>50</sub> 1 – 10 μM) and weak inhibitors (IC<sub>50</sub> >  
368 10 μM) (Krippendorff *et al.*, 2007). Using these criteria, PPF displayed moderate  
369 inhibition of DEF metabolism for CYP's 6Z2 and 6P2, with the remainder being weakly  
370 inhibited. Deltamethrin and permethrin were moderate inhibitors of DEF activity for all  
371 P450s apart from CYP6Z2, which was weakly inhibited by both pyrethroids. As Olyset  
372 Duo nets contain both PPF and permethrin, we also measured PPF inhibition of  
373 permethrin metabolism by CYP6P3 and vice versa (Fig. 1). CYP6P3 was chosen as it  
374 is one of the P450s most frequently found at elevated levels of expression in pyrethroid  
375 resistant populations of *An. gambiae*. Permethrin produced slightly stronger inhibition  
376 of PPF metabolism (IC<sub>50</sub> = 61.2 μM) than PPF inhibition of permethrin metabolism  
377 (IC<sub>50</sub> = 92.7 μM). Overall, the *in vitro* results suggest that the pyrethroids deltamethrin  
378 and permethrin are slightly stronger inhibitors (2 – 3 fold) than PPF against the  
379 pyrethroid metabolizing P450s tested.

380

381 These data indicate that PPF can be metabolized by a wide range of P450s associated  
382 with pyrethroid resistance. In mosquitoes that have elevated levels of expression of  
383 one or more of these enzymes, it is feasible that enhanced metabolism of PPF could  
384 reduce the efficacy of this juvenile hormone analogue. To test this hypothesis we  
385 performed PPF bioassays on insecticide susceptible and resistant strains.

386

387 **3.3 Bioefficacy of PPF against insecticide resistant mosquitoes**

388 The impact of exposure to PPF on metamorphosis and embryogenesis was compared  
389 in the insecticide susceptible Kisumu strain and the multi resistant Tiassalé strain from  
390 Cote d'Ivoire. The dose-response tests showed that SumiLarv® 0.5G affected adult  
391 mosquito emergence in both strains but the minimum dose that inhibited 100 %  
392 emergence was 1 ppb in the insecticide susceptible Kisumu strain and 10 ppb in the  
393 Tiassalé strain. The concentration that resulted in 50 % inhibition of emergence ( $EI_{50}$ )  
394 for the susceptible Kisumu strain was 0.088 ppb (95 % confidence intervals 0.064 –  
395 0.123 ppb) (Fig. 2), similar to values reported for *An. gambiae s.l.* in other studies  
396 (0.025 ppb Kawada (1993), 0.13 ppb (Mbare et al 2013)). In contrast, the  $EI_{50}$  for the  
397 Tiassalé strain was 0.356 ppb ai (0.274 – 0.463) approximately 4-fold higher than the  
398 Kisumu strain. It is important to note that we cannot directly link the higher  $EI_{50}$  for  
399 PPF to the presence of elevated P450s in the Tiassale strain given that only one  
400 pyrethroid resistant population was evaluated and it is not known whether the same  
401 P450s found elevated in adults of this strain are also up-regulated at the larval  
402 stage. Furthermore, the field dose of SumiLarv 0.5G ranges from 10 - 50 ppb so it is  
403 likely that the product would still inhibit development of the Tiassalé strain under field  
404 conditions. However, given the trajectory of increasing pyrethroid resistance in both  
405 *Anopheles* (Ranson and Lissenden, 2016) and *Aedes* mosquitoes (Vontas et al, 2012)  
406 and the growing interest in use of PPF to target immature populations of these vectors  
407 (Kiwari et al, 2015, Abad-Franch et al., 2015;) it is important that further evaluation of  
408 PPF efficacy against field populations is carried out.

409

410 As the sterilizing effect of PPF on mosquito populations has also received considerable  
411 attention for malaria control, with clinical trials of the PPF/permethrin Olyset Duo LLIN  
412 ongoing (Tiono et al, 2015, Sagnon et al., 2015) we also compared inhibition of  
413 embryogenesis in our susceptible and resistant populations. In a narrow bore glass  
414 tube assay, designed to ensure complete contact with the PPF for the duration of the  
415 assay, mosquitoes from the insecticide susceptible Kisumu strain were completely

416 sterilized after a 3 minute exposure to 5.5 mg/m<sup>2</sup> whereas only 75% of Tiassalé  
417 mosquitoes were sterilized by this dose. At half this dose, PPF had no impact on ovary  
418 development in Tiassalé but resulted in 76 % of Kisumu mosquitoes being sterilized  
419 (Fig. 3). Thus higher concentrations of PPF are needed to sterilize the pyrethroid  
420 resistant strain, consistent with the effect on metamorphosis described above.

421

### 422 **3.4 Interactions between PPF and Permethrin.**

423 The *in vitro* analysis demonstrated that the same P450s can bind and metabolize PPF  
424 and pyrethroids. This interaction could have a synergizing effect with one chemical  
425 essentially reducing the rate of depletion of the other such that both chemicals are  
426 more potent when used in combination. As the pyrethroid IC<sub>50</sub>s were generally lower  
427 than for PPF (with the exception of CYP6Z2), pyrethroids might be expected to have  
428 a stronger enhancing effect on PPF activity than vice versa. However, the differences  
429 in IC<sub>50</sub> values were small (~2 fold) and, as the *in vivo* concentrations in mosquitoes  
430 after exposure to products containing PPF and/or permethrin are unknown, such  
431 predictions in isolation are highly speculative. Furthermore, as shown above, the  
432 performance of PPF varies between strains and thus the impact of combining the two  
433 chemistries in vector control products may depend on the level of expression of P450s  
434 in the strain.

435

436 To investigate this further we evaluated the performance of LLINs containing a single  
437 active ingredient versus the combination Olyset Duo LLIN in cone bioassays. The  
438 Tiassalé strain was exposed to four net types, mortality recorded 24 hours after  
439 exposure and surviving mosquitoes were offered a bloodmeal. Ovary development  
440 was assessed after a further 5 days. As expected very low mortality was observed in  
441 the mosquitoes exposed to untreated or PPF only nets (Table 4). Mortality was higher  
442 after exposure to Olyset Duo nets than conventional Olyset nets (2-tailed z test,  
443 p=0.02). All bloodfed mosquitoes exposed to the Olyset or untreated nets developed



444 normal ovaries. In contrast all of the mosquitoes exposed to the 1% PPF net were  
445 sterilized. The number of surviving mosquitoes that successfully bloodfed from the  
446 Olyset Duo arm was small but surprisingly only 60 % of these mosquitoes were  
447 sterilized. The differential sterilizing effect of nets containing 1 % w/w PPF alone and  
448 Olyset Duo (with 1% PPF and 2 % permethrin) was confirmed in follow up cone  
449 bioassay study in which mosquitoes were only exposed for 30 seconds. Here > 87 %  
450 of Tiassalé mosquitoes exposed to PPF nets (n=34 dissections) were sterilized versus  
451 0% for untreated nets (n=39) and only 16 % for Olyset Duo nets (n= 38) (Table S4).

452

453 Taken together these results suggest that PPF *increases* the efficacy of permethrin  
454 but permethrin *reduces* the efficacy of PPF. This is supported by data showing higher  
455 mortality rates in huts with Olyset Duo than with Olyset in areas with resistant  
456 mosquitoes (Ngfour et al 2014 in Benin, Koffi et al, 2015 in Cote d'Ivoire) (although no  
457 increase in the proportion of mosquitoes sterilised in huts containing PPF only nets  
458 versus Olyset Duo nets was observed, as our laboratory data would have predicted).  
459 It is important to note that these experiments are conducted on formulated products,  
460 and although the concentration of permethrin and PPF does not differ between net  
461 types, they may differ in their bleed rates affecting the bioavailability of the two active  
462 ingredients. Further laboratory and field evaluations, against vectors with differing  
463 levels of metabolic resistance, are needed to better predict the performance of  
464 combination products, such as Olyset Duo, in the field.

465

## 466 **Conclusions**

467 Given that pyrethroid resistant populations of malaria vectors are now ubiquitous in  
468 Africa, it is important to evaluate the possible impact of this resistance on the  
469 performance of any new vector control tools. In this study we demonstrated that a  
470 subset of mosquito P450 enzymes responsible for elevated pyrethroid metabolism in  
471 insecticide resistant mosquitoes can also metabolize PPF. As metabolic resistance is

472 an increasingly problematic resistance mechanism in African malaria vectors, there is  
473 a very real concern that PPF resistance may already be present in field population of  
474 *Anopheles* mosquitoes. Although the levels of PPF resistance we observed in the  
475 current study are low, continual monitoring for resistance to this chemistry should be  
476 undertaken in any area employing PPF as a larvicide or considering PPF use for adult  
477 mosquito control.

478

#### 479 **Funding**

480 The research leading to these results has received funding from the European Union  
481 Seventh Framework Programme FP7 (2007-2013) under grant agreement no 265660  
482 AvecNet. N.G was supported by the 'Francisco Jose de Caldas' PhD fellowship from  
483 the Colombian Administrative Department of Science, Technology and Innovation  
484 (COLCIENCIAS).

485

#### 486 **Acknowledgements**

487 We thank Sumitomo Chemicals Ltd for providing the samples of bednets and SumiLarv  
488 for this study and Dr Dave Weetman for helpful comments on the manuscript.

489

#### 490 **References**

- 491 Abad-Franch, F., Zamora-Perea, E., Ferraz, G., Padilla-Torres, S.D., Luz, S.L.B.,  
492 2015. Mosquito-Disseminated Pyriproxyfen Yields High Breeding-Site Coverage  
493 and Boosts Juvenile Mosquito Mortality at the Neighborhood Scale. PLoS Negl.  
494 Trop. Dis. 9. doi:10.1371/journal.pntd.0003702
- 495 Aiku, A.O., Yates, A., Rowland, M., 2006. Laboratory evaluation of pyriproxifen  
496 treated bednets on mosquito fertility and fecundity. A preliminary study. West  
497 Afr. J. Med. 25, 22–26. doi:10.4314/wajm.v25i1.28240
- 498 Bhatt, S., Weiss, D.J., Cameron, E., Bisanzio, D., Mappin, B., Dalrymple, U., 2015.  
499 The effect of malaria control on *Plasmodium falciparum* in Africa between 2000

500 and 2015. *Nature* 526. doi:10.1038/nature15535

501 Carriere, Y., Ellers-Kirk, C., Hartfield, K., Larocque, G., Degain, B., Dutilleul, P.,  
502 Dennehy, T.J., Marsh, S.E., Crowder, D.W., Li, X., Ellsworth, P.C., Naranjo,  
503 S.E., Palumbo, J.C., Fournier, A., Antilla, L., Tabashnik, B.E., 2012. Large-  
504 scale, spatially-explicit test of the refuge strategy for delaying insecticide  
505 resistance. *PNAS* 109, 775–780. doi:10.1073/pnas.1117851109

506 Chandor-Proust, A., Bibby, J., Régent-Kloeckner, M., Roux, J., Guittard-Crilat, E.,  
507 Poupardin, R., Riaz, M.A., Paine, M., Dauphin-Villemant, C., Reynaud, S.,  
508 David, J.-P.P., Regent-Kloeckner, M., Roux, J., Guittard-Crilat, E., Poupardin,  
509 R., Riaz, M.A., Paine, M., Dauphin-Villemant, C., Reynaud, S., David, J.-P.P.,  
510 Régent-Kloeckner, M., Roux, J., Guittard-Crilat, E., Poupardin, R., Riaz, M.A.,  
511 Paine, M., Dauphin-Villemant, C., Reynaud, S., David, J.-P.P., 2013. The  
512 central role of mosquito cytochrome P450 CYP6Zs in insecticide detoxification  
513 revealed by functional expression and structural modelling. *Biochem. J.* 455,  
514 75–85. doi:10.1042/BJ20130577

515 Constant, E. V., Djogbénu, L., Jenkins, A.M., Regna, K., Muskavitch, M.A.T.,  
516 Poupardin, R., Jones, C.M., Essandoh, J., Kétoh, G.K., Paine, M.J.I., Koudou,  
517 B.G., Donnelly, M.J., Ranson, H., Weetman, D., 2014. CYP6 P450 Enzymes  
518 and ACE-1 Duplication Produce Extreme and Multiple Insecticide Resistance in  
519 the Malaria Mosquito *Anopheles gambiae*. *PLoS Genet.* 10, e1004236.  
520 doi:10.1371/journal.pgen.1004236

521 Darriet, F., Corbel, V., 2006. Laboratory evaluation of pyriproxyfen and spinosad,  
522 alone and in combination, against *Aedes aegypti* larvae. *J. Med. Entomol.* 43,  
523 1190–4. doi:10.1603/0022-2585(2006)43[1190:LEOPAS]2.0.CO;2

524 David, J., Ismail, H.M., Chandor-proust, A., Ingraham, M.J., John, M., Paine, I., 2013.  
525 Role of cytochrome P450s in insecticide resistance : impact on the control of  
526 mosquito-borne diseases and use of insecticides on Earth Role of cytochrome  
527 P450s in insecticide resistance : impact on the control of mosquito-borne

528 diseases and use of insecti. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.*

529 Devine, G.J., Perea, E.Z., Killeen, G.F., Stancil, J.D., Clark, S.J., Morrison, A.C.,  
530 2009. Using adult mosquitoes to transfer insecticides to *Aedes aegypti* larval  
531 habitats. *Proc. Natl. Acad. Sci.* 106, 11530–11534.  
532 doi:10.1073/pnas.0901369106

533 Hemingway, J., Vontas, J., Poupardin, R., Raman, J., Lines, J., Schwabe, C., Matias,  
534 A., Kleinschmidt, I., 2013. Country-level operational implementation of the  
535 Global Plan for Insecticide Resistance Management. *Proc. Natl. Acad. Sci. U. S.*  
536 *A.* 110, 9397–402. doi:10.1073/pnas.1307656110

537 Karatolos, N., Williamson, M.S., Denholm, I., Gorman, K., French-Constant, R.H.,  
538 Bass, C., 2012. Over-expression of a cytochrome P450 is associated with  
539 resistance to pyriproxyfen in the greenhouse whitefly *trialeurodes vaporariorum*.  
540 *PLoS One* 7. doi:10.1371/journal.pone.0031077

541 Koffi, A.A., Ahoua Alou, L.P., Djenontin, A., Kabran, J.-P.K., Dosso, Y., Kone, A.,  
542 Moiroux, N., Pennetier, C., 2015. Efficacy of Olyset(®) Duo, a permethrin and  
543 pyriproxyfen mixture net against wild pyrethroid-resistant *Anopheles gambiae*  
544 s.s. from Côte d'Ivoire: an experimental hut trial. *Parasite* 22, 28.  
545 doi:10.1051/parasite/2015028

546 Krippendorff, B.-F., Lienau, P., Reichel, A., Huisinga, W., 2007. Optimizing  
547 classification of drug-drug interaction potential for CYP450 isoenzyme inhibition  
548 assays in early drug discovery. *J. Biomol. Screen. Off. J. Soc. Biomol. Screen.*  
549 12, 92–99. doi:10.1177/1087057106295897

550 Lee, D.-K., 2001. Field evaluation of an insect growth regulator, pyriproxyfen, against  
551 *Aedes togoi* larvae in brackish water in South Korea. *J. Vector Ecol.* 26, 39–42.

552 Mclaughlin, L.A., Niazi, U., Bibby, J., David, J.P., Vontas, J., Hemingway, J., Ranson,  
553 H., Sutcliffe, M.J., Paine, M.J.I., 2008. Characterization of inhibitors and  
554 substrates of *Anopheles gambiae* CYP6Z2. *Insect Mol Biol* 17, 125–135.  
555 doi:DOI 10.1111/j.1365-2583.2007.00788.x

556 Mitchell, S.N., Stevenson, B.J., Muller, P., Wilding, C.S., Egyir-Yawson, a., Field,  
557 S.G., Hemingway, J., Paine, M.J.I., Ranson, H., Donnelly, M.J., 2012.  
558 Identification and validation of a gene causing cross-resistance between  
559 insecticide classes in *Anopheles gambiae* from Ghana. *Proc Natl Acad Sci U S*  
560 *A* 109, 6147–6152. doi:DOI 10.1073/pnas.1203452109

561 Muller, P., Warr, E., Stevenson, B.J., Pignatelli, P.M., Morgan, J.C., Steven, A.,  
562 Yawson, A.E., Mitchell, S.N., Ranson, H., Hemingway, J., Paine, M.J.I.,  
563 Donnelly, M.J., 2008. Field-Caught Permethrin-Resistant *Anopheles gambiae*  
564 Overexpress CYP6P3, a P450 That Metabolises Pyrethroids. *PLoS Genet* 4.  
565 doi:ARTN e1000286DOI 10.1371/journal.pgen.1000286

566 Ngufor, C., N'Guessan, R., Fagbohoun, J., Odjo, A., Malone, D., Akogbeto, M.,  
567 Rowland, M., 2014. Olyset Duo?? (a pyriproxyfen and permethrin mixture net):  
568 An experimental hut trial against pyrethroid resistant *Anopheles gambiae* and  
569 *Culex quinquefasciatus* in southern Benin. *PLoS One* 9.  
570 doi:10.1371/journal.pone.0093603

571 Ohashi, K., Nakada, K., Ishiwatari, T., Miyaguchi, J., Shono, Y., Lucas, J.R., Mito, N.,  
572 2012. Efficacy of pyriproxyfen-treated nets in sterilizing and shortening the  
573 longevity of *Anopheles gambiae* (Diptera: Culicidae). *J. Med. Entomol.* 49,  
574 1052–8. doi:10.1603/ME12006

575 Rami Horowitz, A., Gorman, K., Ross, G., Denholm, I., 2003. Inheritance of  
576 pyriproxyfen resistance in the whitefly, *Bemisia tabaci* (Q biotype), in: *Archives*  
577 *of Insect Biochemistry and Physiology*. pp. 177–186. doi:10.1002/arch.10115

578 Ranson, H., Lissenden, 2016. Insecticide resistance in African *Anopheles* mosquitos:  
579 A worsening situation that needs urgent action to maintain malaria control.  
580 *Trends Parasitol.* In press, 187–196. doi:10.1016/j.pt.2015.11.010

581 Sagnon, N., Pinder, M., Tchicaya, E.F., Tiono, A.B., Faragher, B., Ranson, H.,  
582 Lindsay, S.W., 2015. To assess whether addition of pyriproxyfen to long-lasting  
583 insecticidal mosquito nets increases their durability compared to standard long-

584 lasting insecticidal mosquito nets: study protocol for a randomised controlled  
585 trial. *Trials* 16, 195. doi:10.1186/s13063-015-0700-7

586 Stevenson, B.J., Bibby, J., Pignatelli, P., Muangnoicharoen, S., O'Neill, P.M., Lian,  
587 L.Y., Muller, P., Nikou, D., Steven, A., Hemingway, J., Sutcliffe, M.J., Paine,  
588 M.J.I., 2011. Cytochrome P450 6M2 from the malaria vector *Anopheles*  
589 *gambiae* metabolizes pyrethroids: Sequential metabolism of deltamethrin  
590 revealed. *Insect Biochem Mol Biol* 41, 492–502. doi:DOI  
591 10.1016/j.ibmb.2011.02.003

592 Stevenson, B.J., Pignatelli, P., Nikou, D., Paine, M.J.I., 2012. Pinpointing P450s  
593 Associated with Pyrethroid Metabolism in the Dengue Vector, *Aedes aegypti*:  
594 Developing New Tools to Combat Insecticide Resistance. *PLoS Negl Trop Dis*  
595 6. doi:Artn E1595Doi 10.1371/Journal.Pntd.0001595

596 Tiono, A.B., Pinder, M., N'Fale, S., Faragher, B., Smith, T., Silkey, M., Ranson, H.,  
597 Lindsay, S.W., 2015. The AvecNet Trial to assess whether addition of  
598 pyriproxyfen, an insect juvenile hormone mimic, to long-lasting insecticidal  
599 mosquito nets provides additional protection against clinical malaria over current  
600 best practice in an area with pyrethroid-resist. *Trials* 16, 1–12.  
601 doi:10.1186/s13063-015-0606-4

602 Toé, K.H., N'Falé, S., Dabiré, R.K., Ranson, H., Jones, C.M., 2015. The recent  
603 escalation in strength of pyrethroid resistance in *Anopheles coluzzi* in West  
604 Africa is linked to increased expression of multiple gene families. *BMC*  
605 *Genomics* 16, 1–11. doi:10.1186/s12864-015-1342-6

606 Tsunoda, T., Kawada, H., Huynh, T.T.T., Luu, L. Le, Le, S.H., Tran, H.N., Vu, H.T.Q.,  
607 Le, H.M., Hasebe, F., Tsuzuki, A., Takagi, M., 2013. Field trial on a novel control  
608 method for the dengue vector, *Aedes aegypti* by the systematic use of Olyset®  
609 Net and pyriproxyfen in Southern Vietnam. *Parasit. Vectors* 6, 6.  
610 doi:10.1186/1756-3305-6-6

611 Vijayan, V.A., Sathish Kumar, B.Y., Ganesh, K.N., Urmila, J., Fakoorziba, M.R.,

612 Makkapati, A.K., 2007. Efficacy of piperonyl butoxide (PBO) as a synergist with  
613 deltamethrin on five species of mosquitoes. *J. Commun. Dis.* 39, 159–163.  
614 doi:10.1006/taap.2001.9347

615 Zhang, L., Kasai, S., Shono, T., 1998. In vitro metabolism of pyriproxyfen by  
616 microsomes from susceptible and resistant housefly larvae. *Arch. Insect*  
617 *Biochem. Physiol.* 37, 215–224. doi:10.1002/(SICI)1520-  
618 6327(1998)37:3<215::AID-ARCH4>3.0.CO;2-R

619

620 **Figure captions**

621

622 **Figure 1. Determination of IC<sub>50</sub> values of permethrin and PPF in P450**  
623 **metabolism.** Dose-response analysis of the inhibitory effect of (A) pyriproxyfen on  
624 permethrin metabolism and (B) permethrin on pyriproxyfen metabolism.

625

626 **Figure 2. SumiLarv emergence inhibition curves for two strains of *An. gambiae*.**  
627 Emergence inhibition dose response curves for the insecticide susceptible Kisumu  
628 strain (continuous line) and insecticide resistant Tiassalé strain (dotted line). The grey  
629 dotted lines represent 95 % upper and lower limits.

630

631 **Figure 3. Effect of pyriproxyfen on egg development for two strains of *An.***  
632 ***gambiae*.** Proportions of normal/abnormal ovaries of mosquitoes from Tiassale and  
633 Kisumu strains exposed to three different concentrations of pyriproxyfen. The number  
634 over each bar corresponds to the sample size for each treatment.

635

636



637 **Table 1. Kinetic parameters for DEF**

P450	Kinetic parameters for DEF			
	Single plasmid expression		Dual plasmid expression	
	$K_M$ ( $\mu\text{M}$ )	$V_{\text{max}}$ (RFU/sec)	$K_M$ ( $\mu\text{M}$ )	$V_{\text{max}}$ (RFU/sec)
<b>CYP6M2</b>	0.4 ± 0.02	902.2 ± 106.99	0.5 ± 0.01	292.5 ± 38.05
<b>CYP6P3</b>	0.7 ± 0.10	54.4 ± 6.52	0.9 ± 0.09	14.8 ± 4.89
<b>CYP6P2</b>	nt	nt	1.4 ± 0.02	300.6 ± 12.00
<b>CYP6P4</b>	nt	nt	1.0 ± 0.04	24.2 ± 1.26
<b>CYP9J5</b>	nt	nt	3.4 ± 0.21	265.1 ± 28.75
<b>CYP6Z2</b>	nt	nt	0.5 ± 0.3	43.7 ± 8.9

nt = not tested ; (mean ± SD)

638

639

640 **Table 2. Pyriproxyfen metabolism by mosquito P450s.**

P450	% PPF depletion		Inhibition ratio (%) <sup>a</sup>
	- PBO	+ PBO	
<b>CYP6M2</b>	30.93 ± 4.65	1.44 ± 0.67	95.3
<b>CYP6P2</b>	58.03 ± 1.35	6.45 ± 3.22	91.0
<b>CYP6P3</b>	100.0 ± 0.01	8.68 ± 1.74	91.3
<b>CYP6P4</b>	81.63 ± 0.63	4.44 ± 1.99	94.6
<b>CYP6P5</b>	39.96 ± 1.04	2.40 ± 2.01	95.4
<b>CYP9J5</b>	24.78 ± 2.13	0.08 ± 0.15	99.6
<b>CYP6Z2</b>	66.26 ± 3.02	8.41 ± 1.58	87.3

<sup>a</sup> reduction of PPF depletion in percentage caused by the inhibitory effect of PBO; (mean ± SD)

641

642

643

644

645

646

647

648

649 **Table 3. IC<sub>50</sub> values for mosquito P450s.**

P450	IC <sub>50</sub> (µM)		
	Pyriproxyfen	Deltamethrin	Permethrin
CYP6M2	14.14	4.24	8.07
CYP6Z2	2.23	13.99	13.72
CYP6P2	9.95	4.97	8.61
CYP6P3	15.82	3.17	6.77
CYP9J5	18.96	6.05	6.47

657

658

659 **Table 4. Impact of exposure to LLINs containing permethrin and/or pyriproxyfen**

660 **on mosquito mortality and egg development.** *An. gambiae* Tiassalé strain were  
 661 exposed to the LLINs for 3 min. Mortality was measured 24 hours later and surviving  
 662 mosquitoes offered a blood meal. Ovary dissections were performed 5 days later. n  
 663 bloodfed accounts for the number of surviving mosquitoes that fed on blood and  
 664 survived for five days until ovary dissections.

665

LLIN	n	Mortality % (95%CI)	n bloodfed	Abnormal	% Sterilised
Untreated	45	2.22 (0.12-13.2)	23	0	0
Olyset	46	30.4 (18.2-45.9)	19	0	0
Olyset Duo	46	54.3 (39.2-68.8)	10	6	60
PPF	46	2.17 (0.11-13.0)	35	35	100


666

667

668

669

670



671


672

673 **Figure 1. Determination of IC<sub>50</sub> values of permethrin and PPF in P450**

674 **metabolism.** Dose-response analysis of the inhibitory effect of (A) pyriproxyfen on

675 permethrin metabolism and (B) permethrin on pyriproxyfen metabolism.

676



677

678

679


680 **Figure 2. SumiLarv emergence inhibition curves for two strains of *An. gambiae*.**

681 Emergence inhibition dose response curves for the insecticide susceptible Kisumu

682 strain (continuous line) and insecticide resistant Tiassalé strain (dotted line). The grey

683 dotted lines represent 95 % upper and lower limits.

684



685

686

687 **Figure 3. Effect of pyriproxyfen on egg development for two strains of *An.***

688 ***gambiae*.** Proportions of normal/abnormal ovaries of mosquitoes from Tiassale and

689 Kisumu strains exposed to three different concentrations of pyriproxyfen. The number

690 over each bar corresponds to the sample size for each treatment.

691

692

693

694

695  
696  
697  
698

**Table S1. Oligonucleotide sequences used for cloning *An. gambiae* P450 genes.**

Target	Orientation	Sequence, 5' to 3'
<b>ompA</b>	F	GGAATT <b>CATATG</b> AAAAAGACAGCTATCGCG
<b>CYP6P1</b>	R (L)	CCGAGCAGTGACATCGGGACGGCCTGCGCTACGGTAGCGAA
<b>CYP6P1</b>	R	ATAAGAAT <b>GCGGCCGC</b> TACACCTGCACGATGCGC
<b>CYP6P2</b>	R (L)	GGTCAAGAGCTCCATCGGGACGGCCTGCGCTACGGTAGCGAA
<b>CYP6P2</b>	R	ATAAGAAT <b>GCGGCCGC</b> TCAAAGCTTCTCCACCTCCAG
<b>CYP6P4</b>	R (L)	GCTTAACAGATCCATCGGGACGGCCTGCGCTACGGTAGCGAA
<b>CYP6P4</b>	R	ATAAGAAT <b>GCGGCCGC</b> CTATATCTTATCAACCTTCAG
<b>CYP6P5</b>	R (L)	CGTAACGGGCTCCATCGGGACGGCCTGCGCTACGGTAGCGAA
<b>CYP6P5</b>	R	ATAAGAAT <b>GCGGCCGC</b> CTACGCAATCTTATCCACCTTCAGG
<b>CYP9J5</b>	R (L)	TCAAACCTGATCTCCATCGGGACGGCCTGCGCTACGGTAGCGAA
<b>CYP9J5</b>	R	ATAAGAAT <b>GCGGCCGC</b> TCAGTTAGCAGCTTGCTTGC
<b>CYP6M1</b>	R (L)	GGTTGGGAACACATCGGGACGGCCTGCGCTACGGTAGCGAA
<b>CYP6M1</b>	R	ATAAGAAT <b>GCGGCCGC</b> TCAACCTTGCTTCGATTCAG

R (L): reverse "linker" primer complementary to the first 21 bases of the P450 cDNA joined to the last bases of ompA sequence

*Nde*I (CATATG) and *Not*I (GCGGCCGC) restriction sites highlighted in bold

699  
700

701  
702

**Table S2. Accession numbers for P450 clones**

Gene	Reference*	Single nucleotide polymorphism**
<b>CYP6P1</b>	AY028785	1 synonymous, 0 missense
<b>CYP6P2</b>	XM_312047 (AGAP002869)	2 synonymous, 1 missense c.241 G>A; V81I
<b>CYP6P4</b>	XM_312048 (AGAP002867)	0 synonymous, 0 missense
<b>CYP6P5</b>	XM_312049 (AGAP002866)	22 synonymous, 1 missense c.1369 C>T; R457W
<b>CYP9J5</b>	XM_551896 (AGAP012296)	1 synonymous, 0 missense
		23 synonymous, 8 missense
<b>CYP6M1</b>	AY062208.1	c.103 G>A V35I c.232 A>C M78L c.640 G>A V214M c.645 A>C E215D c.720 T>G F240L c.1041 C>G D347E c.1201 T>G S401A c.1264 G>C A422P

\*Genebank accession code for complete cds, in brackets vectorbase code \*\* Polymorphisms detected in our individuals

703  
704  
705

706  
707

**Table S3. P450 yields and CPR activity.**

P450	N <sup>a</sup>	Expression (nmol/L) <sup>b</sup>	Membrane content	
			nmol P450/mg <sup>c</sup>	nmol cyt c/min/mg <sup>d</sup>
CYP6M2 (1)	1	nt	0.054	65
CYP6P3 (1)	1	nt	0.067	620
CYP6M2 (2)	1	nt	0.606	57
CYP6P3 (2)	2	38.8 ± 3.2	0.18 ± 0.02	188.5 ± 51.0
CYP6P2	4	23.1 ± 1.9	0.21 ± 0.02	232.3 ± 76.1
CYP6P4	6	67.9 ± 15.3	0.61 ± 0.14	258.1 ± 100.4
CYP6P5	6	10.7 ± 3.1	0.10 ± 0.02	165.1 ± 71.9
CYP9J5	4	26.0 ± 7.5	0.25 ± 0.07	281.3 ± 113.2
CYP6Z2	2	122.4 ± 24.5	0.92 ± 0.02	245.4 ± 33.4

<sup>a</sup> Number of independent membranes used for yield calculations.

<sup>b</sup> nmol of P450 isolated membrane preparation per litre of bacterial cultures; nt, not tested

<sup>c</sup> P450 concentration in membrane preparation as nmol of P450 per mg of total protein.

<sup>d</sup> CPR activity in membrane preparation measured as nmol of cytochrome c reduced per min per mg of total protein  
Measurements are expressed as means ± standard deviation.

(1) single plasmid, (2) double plasmid

708  
709  
710  
711  
712  
713  
714



715  
 716 **Table S4 Mortality and sterilisation cause by a short-time exposure to two**  
 717 **type of LLINs on Tiassale *An. gambiae* mosquitoes.** Mortality and  
 718 sterilisation on Tiassale multi-resistant mosquitoes after 30 sec exposure to two  
 719 different types of LLINs containing PPF. n bloodfed accounts for the number of  
 720 surviving mosquitoes that fed on blood and survived for five days until ovary  
 721 dissections.

LLIN	n	Mortality % (95%CI)	n bloodfed	Abnormal	% Sterilised
Untreated	39	2.56 (0.13-15.1)	38	0	0
PPF	31	22.6 (10.3-41.5)	24	21	87.5
Olyset Duo	38	15.8 (6.59-31.9)	38	6	15.8

722  
 723  
 724  
 725